Showing 5141-5150 of 5771 results for "".
- Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Millionhttps://modernod.com/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million/2476641/Biogen announced that it has completed its acquisition of gene therapy company Nightstar Therapeutics, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical ass
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Draper James and VSP Eyes of Hope Commit Nearly $4 Million to Fund Eye Care and Eyewear in Support of Young Womenhttps://modernod.com/news/draper-james-and-vsp-eyes-of-hope-commit-nearly-4-million-to-fund-eye-care-and-eyewear-in-support-of-young-women/2476637/More women than men are at risk for vision loss from eye diseases like glaucoma and macular degeneration. To help ensure more women have access to critical eye care, Draper James, the Southern-inspired lifestyle brand founded by Reese Witherspoon, announced a partne
- Phase 1/2 Study Evaluating THR-317 for DME Meets Primary Safety Endpointhttps://modernod.com/news/data-from-phase-1-2-clinical-study-evaluating-thr-317-anti-plgf-for-dme-presented-at-2019-floretina-meeting/2476638/Oxurion NV announced that clinical-stage data from a phase 1/2 study evaluating its anti-placental growth factor candidate THR-317 for the treatment of diabetic macular edema (DME) were presented at the FLORetina 2019 meeting in Florence, Italy. THR-317 (anti-PlGF) is a recombinant humanized mono
- Three-Year Clinical Trial Results Support Iluvien Launch in Europe for Prevention of Relapse in Recurrent Noninfectious Uveitis Affecting the Posterior Segmenthttps://modernod.com/news/three-year-clinical-trial-results-support-iluvien-launch-in-europe-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis-affecting-the-posterior-segment/2476635/Alimera Sciences announced 3-year followup data from the phase 3 clinical trial for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU). The data will support the company’s pla
- Eyenovia Enrolls First Patient in Phase 3 CHAPERONE Study for Progressive Myopiahttps://modernod.com/news/eyenovia-enrolls-first-patient-in-phase-3-chaperone-study-for-progressive-myopia/2476629/Eyenovia announced that it has initiated its MicroPine phase 3 program with the first patient enrolled in its CHAPERONE study, a US-based, multicenter, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. CHAPERO
- Ophtec Partners With VSA in Argentina to Commercialize Ophtec’s Productshttps://modernod.com/news/ophtec-partners-with-vsa-in-argentina-to-commercialize-ophtecs-products/2476630/Ophtec BV announced that it has signed a partnership agreement with VSA to commercialize Ophtec’s products in the Argentinian marketplace. The Precizon IOL line as well as the Artisan and Artiflex line of iris fixated IOLs are some of the products that will be commercialized by VSA. “Ophte
- Re-Vana Therapeutics Names International Experts to Inaugural Scientific Advisory Boardhttps://modernod.com/news/re-vana-therapeutics-names-international-experts-to-inaugural-scientific-advisory-board/2476628/Re-Vana Therapeutics announced the formation of its new Scientific Advisory Board (SAB). The newly appointed SAB will strategically advise and support Re-Vana as it develops innovative therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), dia
- Goldman Sachs Unit to Buy 575 Optometry Practices in $2.7 Billion Dealhttps://modernod.com/news/report-goldman-sachs-unit-to-buy-capital-vision-services-in-2-7-billion-deal/2476625/In one of the largest optometry deals to date, the merchant-banking division of Goldman Sachs Group (West Street Capital Partners VII) announced that it is buying Capital Vision Services, which operates 575 optometry practices, from private-equity firm Altas Partners LP and Canadian pension fund
- OptiKira Awarded Phase 2 SBIR Grant to Support Development of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/optikira-awarded-phase-2-sbir-grant-to-support-development-of-retinitis-pigmentosa-treatment/2476622/OptiKira announced that it was awarded a phase 2 Small Business Innovation Research (SBIR) grant to support continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa (RP). The $1.6M grant will be used to advance one or more of OptiKira’s mo